Androgens and cardiovascular disease

Endocrine Reviews

Volumn 24, Issue 3, 2003, Pages 313-340

  Liu, Peter Y ^a   Death, Alison K ^b   Handelsman, David J ^a  

^a Department of Microbiology and Infectious Diseases   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN; ESTRADIOL; GONADORELIN ANTAGONIST; NANDROLONE DECANOATE; TESTOSTERONE;

AGE DISTRIBUTION; ARTERY DISEASE; CARDIOVASCULAR DISEASE; CAUSE OF DEATH; CEREBROVASCULAR DISEASE; CLINICAL TRIAL; CORONARY ARTERY DISEASE; ERECTILE DYSFUNCTION; GENE CONTROL; HEART FAILURE; HEART VENTRICLE HYPERTROPHY; HORMONE ACTION; HORMONE SENSITIVITY; HUMAN; HYPERTENSION; LIFESPAN; METABOLIC ACTIVATION; MORTALITY; NONHUMAN; PRIORITY JOURNAL; REVIEW; SEX RATIO;

EID: 0038307297     PISSN: 0163769X     EISSN: None     Source Type: Journal    
DOI: 10.1210/er.2003-0005     Document Type: Review

References (405)

1. Murray CJL, Lopez AD 1996 The global burden of disease. Geneva: World Health Organization
2. Willius FA, Dry TJ 1948 A history of the heart and the circulation. Philadelphia: WB Saunders Co.; 15
3. Kalin MF, Zumoff B 1990 Sex hormones and coronary disease: a review of the clinical studies. Steroids 55:330-352
4. Hulley S, Grady D, Bush T, Furberg C, Herrington D, Riggs B, Vittinghoff E 1998 Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. JAMA 280:605-613
5. Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, Jackson RD, Beresford SA, Howard BV, Johnson KC, Kotchen JM, Ockene J 2002 Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 288:321-333
6. Handelsman DJ 1998 The safety of androgens: prostate and cardiovascular disease. In: Wang C, ed. Male reproductive function. Boston: Kluwer Academic Publishers; 173-190
7. Weidemann W, Hanke H 2002 Cardiovascular effects of androgens. Cardiovasc Drug Rev 20:175-198
8. 2002 World Population Data Sheet. Washington, DC: Population Reference Bureau
9. The World Health Report 2002. Geneva: World Health Organization
10. Owens IP 2002 Ecology and evolution. Sex differences in mortality rate. Science 297:2008-2009
11. Ely DL, Salisbury R, Hadi D, Turner M, Johnson ML 1991 Androgen receptor and the testes influence hypertension in a hybrid rat model. Hypertension 17:1104-1110
12. Harrap SB, Wang BZ, MacLellan DG 1992 Renal transplantation between male and female spontaneously hypertensive rats. Hypertension 19:431-434
13. Honda H, Unemoto T, Kogo H 1999 Different mechanisms for testosterone-induced relaxation of aorta between normotensive and spontaneously hypertensive rats. Hypertension 34:1232-1236
14. Ely D, Turner M, Milsted A 2000 Review of the Y chromosome and hypertension. Braz J Med Biol Res 33:679-691
15. Kromhout D, Menotti A, Kesteloot H, Sans S 2002 Prevention of coronary heart disease by diet and lifestyle: evidence from prospective cross-cultural, cohort, and intervention studies. Circulation 105:893-898
16. Barrett-Connor E 1997 Sex differences in coronary heart disease. Why are women so superior? The 1995 Ancel Keys Lecture. Circulation 95:252-264
17. Sackett DL 1979 Bias in analytical research. J Chronic Dis 32:51-63
18. Tracy RE 1966 Sex difference in coronary disease: two opposing views. J Chronic Dis 19:1245-1251
19. Furman RH 1968 Are gonadal hormones (estrogens and androgens) of significance in the development of ischemic heart disease. Ann NY Acad Sci 149:822-833
20. Heller RF, Jacobs HS 1978 Coronary heart disease in relation to age, sex, and the menopause. Br Med J 1:472-474
21. Tunstall-Pedoe H 1998 Myth and paradox of coronary risk and the menopause. Lancet 351:1425-1427
22. Rossouw JE 2002 Hormones, genetic factors, and gender differences in cardiovascular disease. Cardiovasc Res 53:550-557
23. Coronary Drug Project Research Group 1973 The Coronary Drug Project. Findings leading to discontinuation of the 2.5-mg day estrogen group. JAMA 226:652-657
24. Group 1967 Treatment and survival of patients with cancer of the prostate. Surg Gynecol Obstet 124:1011-1017
25. Nieschlag E, Nieschlag S, Behre HM 1993 Lifespan and testosterone. Nature 366:215
26. Jenkins JS 1998 The voice of the castrato. Lancet 351:1877-1880
27. Paternostro G 1994 Longevity and testosterone. Nature 368:408
28. Smith SM 1994 Statistical scrotal effect. Nature 368:501-502
29. Hamilton JB, Mestler GE 1969 Mortality and survival: comparison of eunuchs with intact men and women in a mentally retarded population. J Gerontol 24:395-411
30. Hawke CC 1950 Castration and sex crimes. J Kans Med Soc 51:470-475
31. Eyman RK, Grossman HJ, Chaney RH, Call TL 1990 The life expectancy of profoundly handicapped people with mental retardation. N Engl J Med 323:584-589
32. Hamilton JB, Hamilton RS, Mestler GE 1969 Duration of life and causes of death in domestic cats: influence of sex, gonadectomy, and inbreeding. J Gerontol 24:427-437
33. Michell AR 1999 Longevity of British breeds of dog and its relationships with sex, size, cardiovascular variables and disease. Vet Rec 145:625-629
34. Waters DJ, Shen S, Glickman LT 2000 Life expectancy, antagonistic pleiotropy, and the testis of dogs and men. Prostate 43:272-277
35. Talbert GB, Hamilton JB 1965 Duration of life in Lewis strain of rats after gonadectomy at birth and at older ages. J Gerontol 20:489-491
36. Quigley CA, DeBellis A, Marschke KB, El-Awady MK, Wilson EM, French FF 1995 Androgen receptor defects: historical, clinical and molecular perspectives. Endocr Rev 16:271-321
37. van Kesteren P, Asscheman H, Megens JAJ, Gooren LJG 1997 Mortality and morbidity in transsexual subjects treated with cross-sex hormones. Clin Endocrinol (Oxf) 47:337-342
38. Wild S, Pierpoint T, McKeigue P, Jacobs H 2000 Cardiovascular disease in women with polycystic ovary syndrome at long-term follow-up: a retrospective cohort study. Clin Endocrinol (Oxf) 52:595-600
39. Pierpoint T, McKeigue PM, Isaacs AJ, Wild SH, Jacobs HS 1998 Mortality of women with polycystic ovary syndrome at long-term follow-up. J Clin Epidemiol 51:581-586
40. Dahlgren E, Johansson S, Lindstedt G, Knutsson F, Oden A, Janson PO, Mattson LA, Crona N, Lundberg PA 1992 Women with polycystic ovary syndrome wedge resected in 1956 to 1965: a long-term follow-up focusing on natural history and circulating hormones. Fertil Steril 57:505-513
41. Elting MW, Korsen TJ, Bezemer PD, Schoemaker J 2001 Prevalence of diabetes mellitus, hypertension and cardiac complaints in a follow-up study of a Dutch PCOS population. Hum Reprod 16:556-560
42. Wild S, Pierpoint T, Jacobs H, McKeigue P 2000 Long-term consequences of polycystic ovary syndrome: results of a 31 year follow-up study. Hum Fertil (Camb) 3:101-105
43. Birdsall MA, Farquhar CM, White HD 1997 Association between polycystic ovaries and extent of coronary artery disease in women having cardiac catheterization. Ann Intern Med 126:32-35
44. Dahlgren E, Janson PO, Johansson S, Lapidus L, Oden A 1992 Polycystic ovary syndrome and risk for myocardial infarction. Evaluated from a risk factor model based on a prospective population study of women. Acta Obstet Gynecol Scand 71:599-604
45. Rockhold RW 1993 Cardiovascular toxicity of anabolic steroids. Annu Rev Pharmacol Toxicol 33:497-520
46. Melchert RB, Welder AA 1995 Cardiovascular effects of androgenic-anabolic steroids. Med Sci Sports Exerc 27:1252-1262
47. Sullivan ML, Martinez CM, Gennis P, Gallagher EJ 1998 The cardiac toxicity of anabolic steroids. Prog Cardiovasc Dis 41:1-15
48. Maron BJ, Shirani J, Poliac LC, Mathenge R, Roberts WC, Mueller FO 1996 Sudden death in young competitive athletes. Clinical, demographic, and pathological profiles. JAMA 276:199-204
49. Parssinen M, Seppala T 2002 Steroid use and long-term health risks in former athletes. Sports Med 32:83-94
50. Franke WW, Berendonk B 1997 Hormonal doping and androgenization of athletes: a secret program of the German Democratic Republic government. Clin Chem 43:1262-1279
51. Sarna S, Sahi T, Koskenvuo M, Kaprio J 1993 Increased life expectancy of world class male athletes. Med Sci Sports Exerc 25:237-244
52. Menotti A, Amici E, Gambelli GC, Milazzotto F, Bellotti P, Capocaccia R, Giuli B 1990 Life expectancy in Italian track and field athletes. Eur J Epidemiol 6:257-260
53. van Saase JL, Noteboom WM, Vandenbroucke JP 1990 Longevity of men capable of prolonged vigorous physical exercise: a 32 year follow up of 2259 participants in the Dutch eleven cities ice skating tour. BMJ 301:1409-1411
54. Parssinen M, Kujala U, Vartiainen E, Sarna S, Seppala T 2000 Increased premature mortality of competitive powerlifters suspected to have used anabolic agents. Int J Sports Med 21:225-227
55. Heinlein CA, Chang C 2002 Androgen receptor (AR) coregulators: an overview. Endocr Rev 23:175-200
56. Gregory CW, He B, Wilson EM 2001 The putative androgen receptor-A form results from in vitro proteolysis. J Mol Endocrinol 27:309-319
57. Misiti S, Schomburg L, Yen PM, Chin WW 1998 Expression and hormonal regulation of coactivator and corepressor genes. Endocrinology 139:2493-2500
58. Magklara A, Brown TJ, Diamandis EP 2002 Characterization of androgen receptor and nuclear receptor co-regulator expression in human breast cancer cell lines exhibiting differential regulation of kallikreins 2 and 3. Int J Cancer 100:507-514
59. Gregory CW, He B, Johnson RT, Ford OH, Mohler JL, French FS, Wilson EM 2001 A mechanism for androgen receptor-mediated prostate cancer recurrence after androgen deprivation therapy. Cancer Res 61:4315-4319
60. Nelson KA, Witte JS 2002 Androgen receptor CAG repeats and prostate cancer. Am J Epidemiol 155:883-890
61. Zitzmann M, Brune M, Kornmann B, Gromoll J, von Eckardstein S, von Eckardstein A, Nieschlag E 2001 The CAG repeat polymorphism in the AR gene affects high density lipoprotein cholesterol and arterial vasoreactivity. J Clin Endocrinol Metab 86:4867-4873
62. Zitzmann M, Brune M, Kornmann B, Gromoll J, Junker R, Nieschlag E 2001 The CAG repeat polymorphism in the androgen receptor gene affects bone density and bone metabolism in healthy males. Clin Endocrinol (Oxf) 55:649-657
63. von Eckardstein S, Syska A, Gromoll J, Kamischke A, Simoni M, Nieschlag E 2001 Inverse correlation between sperm concentration and number of androgen receptor CAG repeats in normal men. J Clin Endocrinol Metab 86:2585-2590
64. Walcott JL, Merry DE 2002 Trinucleotide repeat disease. The androgen receptor in spinal and bulbar muscular atrophy. Vitam Horm 65:127-147
65. Yu B, Handelsman DJ 2001 Pharmacogenetic polymorphisms of the AR and metabolism and susceptibility to hormone-induced azoospermia. J Clin Endocrinol Metab 86:4406-4411
66. Edwards JP, West SJ, Pooley CL, Marschke KB, Farmer LJ, Jones TK 1998 New nonsteroidal androgen receptor modulators based on 4-(trifluoromethyl)-2(1H)-pyrrolidino[3,2-g] quinolinone. Bioorg Med Chem Lett 8:745-750
67. Dalton JT, Mukherjee A, Zhu Z, Kirkovsky L, Miller DD 1998 Discovery of nonsteroidal androgens. Biochem Biophys Res Commun 244:1-4
68. Yin D, Gao W, Kearbey JD, Xu H, Chung K, He Y, Marhefka CA, Veverka KA, Miller DD, Dalton JT 2002 Pharmacodynamics of selective androgen receptor modulators (SARMs). J Pharmacol Exp Ther 304:1334-1340
69. Losel R, Wehling M 2003 Nongenomic actions of steroid hormones. Nat Rev Mol Cell Biol 4:46-55
70. Heinlein CA, Chang C 2002 The roles of androgen receptors and androgen-binding proteins in nongenomic androgen actions. Mol Endocrinol 16:2181-2187
71. Kousteni S, Chen JR, Bellido T, Han L, Ali AA, O'Brien CA, Plotkin L, Fu Q, Mancino AT, Wen Y, Vertino AM, Powers CC, Stewart SA, Ebert R, Parfitt AM, Weinstein RS, Jilka RL, Manolagas SC 2002 Reversal of bone loss in mice by nongenotropic signaling of sex steroids. Science 298:843-846
72. Falkenstein E, Tillmann HC, Christ M, Feuring M, Wehling M 2000 Multiple actions of steroid hormones-a focus on rapid, nongenomic effects. Pharmacol Rev 52:513-556
73. Gerdes D, Wehling M, Leube B, Falkenstein E 1998 Cloning and tissue expression of two putative steroid membrane receptors. Biol Chem 379:907-911
74. Bernauer S, Wehling M, Gerdes D, Falkenstein E 2001 The human membrane progesterone receptor gene: genomic structure and promoter analysis. DNA Seq 12:13-25
75. Zhu Y, Rice CD, Pang Y, Pace M, Thomas P 2003 Cloning, expression, and characterization of a membrane progestin receptor and evidence it is an intermediary in meiotic maturation of fish oocytes. Proc Natl Acad Sci USA 100:2231-2236
76. Luzardo OP, Machin RP, Diaz-Chico BN, Fernandez L 2000 Photoaffinity labeling identification of a specific binding protein for the anabolic steroids stanozolol and danazol: an oligomeric protein regulated by age, pituitary hormones, and ethinyl estradiol. Endocrinology 141:3377-3387
77. Liu D, Dillon JS 2002 Dehydroepiandrosterone activates endothelial cell nitric-oxide synthase by a specific plasma membrane receptor coupled to Gα(i2,3). J Biol Chem 277:21379-21388
78. Kahn SM, Hryb DJ, Nakhla AM, Romas NA, Rosner W 2002 Sex hormone-binding globulin is synthesized in target cells. J Endocrinol 175:113-120
79. Grino PB, Griffin JE, Wilson JD 1990 Testosterone at high concentrations interacts with the human androgen receptor similarly to dihydrotestosterone. Endocrinology 126:1165-1172
80. George FW, Russell DW, Wilson JD 1991 Feed-forward control of prostate growth: dihydrotestosterone induces expression of its own biosynthetic enzyme, steroid 5α-reductase. Proc Natl Acad Sci USA 88:8044-8047
81. Eicheler W, Tuohimaa P, Vilja P, Adermann K, Forssmann WG, Aumuller G 1994 Immunocytochemical localization of human 5 α-reductase 2 with polyclonal antibodies in androgen target and non-target human tissues. J Histochem Cytochem 42:667-675
82. Eicheler W, Dreher M, Hoffmann R, Happle R, Aumuller G 1995 Immunohistochemical evidence for differential distribution of 5 α-reductase isoenzymes in human skin. Br J Dermatol 133:371-376
83. Milewich L, Kaimal V, Johnson AR 1987 Steroid 5α-reductase activity in endothelial cells from human umbilical cord vessels. J Steroid Biochem 26:561-567
84. Fujimoto R, Morimoto I, Morita E, Sugimoto H, Ito Y, Eto S 1994 Androgen receptors, 5α-reductase activity and androgen-dependent proliferation of vascular smooth muscle cells. J Steroid Biochem Mol Biol 50:169-174
85. Martel C, Melner MH, Gagne D, Simard J, Labrie F 1994 Widespread tissue distribution of steroid sulfatase, 3β-hydroxysteroid dehydrogenase / δ 5-δ 4 isomerase (3β-HSD), 17β-HSD 5α-reductase and aromatase activities in the rhesus monkey. Mol Cell Endocrinol 104:103-111
86. Matsuda K, Mathur RS, Ullian ME, Halushka PV 1995 Sex steroid regulation of thromboxane A2 receptors in cultured rat aortic smooth muscle cells. Prostaglandins 49:183-196
87. Higashiura K, Blaney B, Morgan E, Mathur RS, Halushka PV 1996 Inhibition of testosterone 5α-reductase: evidence for tissue-specific regulation of thromboxane A2 receptors. J Pharmacol Exp Ther 279:1386-1391
88. Harada N, Sasano H, Murakami H, Ohkuma T, Nagura H, Takagi Y 1999 Localized expression of aromatase in human vascular tissues. Circ Res 84:1285-1291
89. Sasano H, Murakami H, Shizawa S, Satomi S, Nagura H, Harada N 1999 Aromatase and sex steroid receptors in human vena cava. Endocr J 46:233-242
90. Murakami H, Harada N, Sasano H 2001 Aromatase in atherosclerotic lesions of human aorta. J Steroid Biochem Mol Biol 79:67-74
91. Nathan L, Shi W, Dinh H, Mukherjee TK, Wang X, Lusis AJ, Chaudhuri G 2001 Testosterone inhibits early atherogenesis by conversion to estradiol: critical role of aromatase. Proc Natl Acad Sci USA 98:3589-3593
92. Diano S, Horvath TL, Mor G, Register T, Adams M, Harada N, Naftolin F 1999 Aromatase and estrogen receptor immunoreactivity in the coronary arteries of monkeys and human subjects. Menopause 6:21-28
93. Bayard F, Clamens S, Meggetto F, Blaes N, Delsol G, Faye JC 1995 Estrogen synthesis, estrogen metabolism, and functional estrogen receptors in rat arterial smooth muscle cells in culture. Endocrinology 136:1523-1529
94. Gyllenborg J, Rasmussen SL, Borch-Johnsen K, Heitmann BL, Skakkebaek NE, Juul A 2001 Cardiovascular risk factors in men: the role of gonadal steroids and sex hormone-binding globulin. Metabolism 50:882-888
95. Verrneulen A, Verdonck L, Kaufman JM 1999 A critical evaluation of simple methods for the estimation of free testosterone in serum. J Clin Endocrinol Metab 84:3666-3672
96. Morley JE, Patrick P, Perry 3rd HM 2002 Evaluation of assays available to measure free testosterone. Metabolism 51:554-559
97. Edwards P, Ekins R 1988 The "Pardridge" hypotheses relating to the role of hormone binding proteins in hormone delivery: a critique. Steroids 52:367-368
98. Ekins R 1990 Measurement of free hormones in blood. Endocr Rev 11:5-46
99. Pardridge WM 1986 Serum bioavailability of sex steroid hormones. Clin Endocrinol Metab 15:259-278
100. Pardridge WM 1987 Plasma protein-mediated transport of steroid and thyroid hormones. Am J Physiol 252:E157-E164
101. Pardridge WM 1988 Selective delivery of sex steroid hormones to tissues by albumin and by sex hormone-binding globulin. Oxf Rev Reprod Biol 10:237-292
102. Mendel CM 1989 The free hormone hypothesis: a physiologically based mathematical model. Endocr Rev 10:232-274
103. Ekins R 1993 Analytic measurements of free thyroxine. Clin Lab Med 13:599-630
104. Dunn JF, Nisula BC, Rodbard D 1981 Transport of steroid hormones: binding of 21 endogenous steroids to both testosterone-binding globulin and corticosteroid-binding globulin in human plasma. J Clin Endocrinol Metab 53:58-68
105. Rosner W, Hryb DJ, Khan MS, Nakhla AM, Romas NA 1999 Androgen and estrogen signaling at the cell membrane via G-proteins and cyclic adenosine monophosphate. Steroids 64:100-106
106. von Schoultz B, Carlstrom K 1989 On the regulation of sex-hormone-binding globulin. A challenge of an old dogma and outlines of an alternative mechanism. J Steroid Biochem Mol Biol 32:327-334
107. Pugeat M, Moulin P, Cousin P, Fimbel S, Nicolas MH, Crave JC, Lejeune H 1995 Interrelations between sex hormone-binding globulin (SHBG), plasma lipoproteins and cardiovascular risk. J Steroid Biochem Mol Biol 53:567-572
108. Haffner SM 1996 Sex hormone-binding protein, hyperinsulinemia, insulin resistance and noninsulin-dependent diabetes. Horm Res 45:233-237
109. Tchernof A, Despres JP 2000 Sex steroid hormones, sex hormone-binding globulin, and obesity in men and women. Horm Metab Res 32:526-536
110. Reventos J, Sullivan PM, Joseph DR, Gordon JW 1993 Tissue-specific expression of the rat androgen-binding protein/sex hormone-binding globulin gene in transgenic mice. Mol Cell Endocrinol 96:69-73
111. Kapoor P, Luttrell BM, Williams D 1993 The free androgen index is not valid for adult males. J Steroid Biochem Mol Biol 45:325-326
112. Rosner W 1997 Errors in the measurement of plasma free testosterone. J Clin Endocrinol Metab 82:2014-2015
113. Winters SJ, Kelley DE, Goodpaster B 1998 The analog free testosterone assay: are the results in men clinically useful? Clin Chem 44:2178-2182
114. Rosner W 2001 An extraordinarily inaccurate assay for free testosterone is still with us. J Clin Endocrinol Metab 86:2903
115. Barker DJP 1998 Mothers, babies and health in later life. 2nd ed. Edinburgh: Churchill Livingstone
116. Hales CN, Barker DJ 2001 The thrifty phenotype hypothesis. Br Med Bull 60:5-20
117. Barker DJ, Forsen T, Eriksson JG, Osmond C 2002 Growth and living conditions in childhood and hypertension in adult life: a longitudinal study. J Hypertens 20:1951-1956
118. Eriksson JG, Forsen T, Tuomilehto J, Osmond C, Barker DJ 2001 Early growth and coronary heart disease in later life: longitudinal study. BMJ 322:949-953
119. Plut C, Ribiere C, Giudicelli Y, Dausse JP 2002 Gender differences
120. Arnold AP, Gorski RA 1984 Gonadal steroid induction of structural sex differences in the central nervous system. Annu Rev Neurosci 7:413-442
121. Rajfer J, Coffey DS 1978 Sex steroid imprinting of the immature prostate. Long-term effects. Invest Urol 16:186-190
122. Singh J, Handelsman DJ 1999 Imprinting by neonatal sex steroids on the structure and function of the mature mouse prostate. Biol Reprod 61:200-208
123. Prins GS, Birch L, Couse JF, Choi I, Katzenellenbogen B, Korach KS 2001 Estrogen imprinting of the developing prostate gland is mediated through stromal estrogen receptor α: studies with αERKO and βERKO mice. Cancer Res 61:6089-6097
124. Gooren LJ 2001 Gender identity and sexual behavior. In: DeGroot LJ, ed. Endocrinology. 4th ed. Philadelphia: WB Saunders Co.; 2033-2042
125. Hamm Jr T, Kaplan J, Clarkson T, Bullock B 1983 Effects of gender and social behaviour on the development of coronary atherosclerosis in cynomolgus monkeys. Atherosclerosis 48:221-233
126. Holm P, Andersen HL, Arroe G, Stender S 1998 Gender gap in aortic cholesterol accumulation in cholesterol-clamped rabbits: role of the endothelium and mononuclear-endothelial cell interaction. Circulation 98:2731-2737
127. Hayashi T, Fukuto JM, Ignarro LJ, Chaudhuri G 1995 Gender differences in atherosclerosis: possible role of nitric oxide. J Cardiovasc Pharmacol 26:792-802
128. Caligiuri G, Nicoletti A, Zhou X, Tornberg I, Hansson GK 1999 Effects of sex and age on atherosclerosis and autoimmunity in apoE-deficient mice. Atherosclerosis 145:301-308
129. Tangirala RK, Rubin EM, Palinski W 1995 Quantitation of atherosclerosis in murine models: correlation between lesions in the aortic origin and in the entire aorta, and differences in the extent of lesions between sexes in LDL receptor-deficient and apolipoprotein E-deficient mice. J Lipid Res 36:2320-2328
130. Trieu VN, Uckun FM 1998 Male-associated hypertension in LDL-R deficient mice. Biochem Biophys Res Commun 247:277-279
131. Johnson RC, Chapman SM, Dong ZM, Ordovas JM, Mayadas TN, Herz J, Hynes RO, Schaefer EJ, Wagner DD 1997 Absence of P-selectin delays fatty streak formation in mice. J Clin Invest 99:1037-1043
132. Li AC, Brown KK, Silvestre MJ, Willson TM, Palinski W, Glass CK 2000 Peroxisome proliferator-activated receptor γ ligands inhibit development of atherosclerosis in LDL receptor-deficient mice. J Clin Invest 106:523-531
133. von Dehn G, von Dehn O, Volker W, Langer C, Weinbauer GF, Behre HM, Nieschlag E, Assmann G, von Eckardstein A 2001 Atherosclerosis in apolipoprotein E-deficient mice is decreased by the suppression of endogenous sex hormones. Horm Metab Res 33:110-114
134. Paigen B, Morrow A, Brandon C, Mitchell D, Holmes P 1985 Variation in susceptibility to atherosclerosis among inbred strains of mice. Atherosclerosis 57:65-73
135. Paigen B, Holmes PA, Mitchell D, Albee D 1987 Comparison of atherosclerotic lesions and HDL-lipid levels in male, female, and testosterone-treated female mice from strains C57BL/6, BALB/c, and C3H. Atherosclerosis 64:215-221
136. Napoli C, de Nigris F, Welch JS, Calara FB, Stuart RO, Glass CK, Palinski W 2002 Maternal hypercholesterolemia during pregnancy promotes early atherogenesis in LDL receptor-deficient mice and alters aortic gene expression determined by microarray. Circulation 105:1360-1367
137. Wang X, Paigen B 2002 Comparative genetics of atherosclerosis and restenosis: exploration with mouse models. Arterioscler Thromb Vasc Biol 22:884-886
138. Harmon KJ, Couper LL, Lindner V 2000 Strain-dependent vascular remodeling phenotypes in inbred mice. Am J Pathol 156:1741-1748
139. Kuhel DG, Zhu B, Witte DP, Hui DY 2002 Distinction in genetic determinants for injury-induced neointimal hyperplasia and diet-induced atherosclerosis in inbred mice. Arterioscler Thromb Vasc Biol 22:955-960
140. Ruygrok PN, Webster MW, de Valk V, van Es GA, Ormiston JA, Morel MA, Serruys PW 2001 Clinical and angiographic factors associated with asymptomatic restenosis after percutaneous coronary intervention. Circulation 104:2289-2294
141. Larsen BA, Nordestgaard B, Stender S, Kjeldsen K 1993 Effect of testosterone on atherogenesis in cholesterol-fed rabbits with similar plasma cholesterol levels. Atherosclerosis 99:79-86
142. Bruck B, Brehme U, Gugel N, Hanke S, Finking G, Lutz C, Benda N, Schmahl FW, Haasis R, Hanke H 1997 Gender-specific differences in the effects of testosterone and estrogen on the development of atherosclerosis in rabbits. Arterioscler Thromb Vasc Biol 17:2192-2199
143. Alexandersen P, Haarbo J, Bryjalsen I, Lawetz H, Christiansen C 1999 Natural androgens inhibit male atherosclerosis. A study in castrated, cholesterol-fed rabbits. Circ Res 84:813-819
144. Gordon GB, Bush DE, Weisman HF 1988 Reduction of atherosclerosis by administration of dehydroepiandrosterone. A study in the hypercholesterolemic New Zealand white rabbit with aortic intimal injury. J Clin Invest 82:712-720
145. Arad Y, Badimon JJ, Badimon L, Hembree WC, Ginsberg HN 1989 Dehydroepiandrosterone feeding prevents aortic fatty streak formation and cholesterol accumulation in cholesterol-fed rabbit. Arteriosclerosis 9:159-166
146. Eich DM, Nestler JE, Johnson DE, Dworkin GH, Ko D, Wechsler AS, Hess ML 1993 Inhibition of accelerated coronary atherosclerosis with dehydroepiandrosterone in the heterotopic rabbit model of cardiac transplantation. Circulation 87:261-269
147. Fogelberg M, Bjorkhem I, Diczfalusy U, Henriksson P 1990 Stanozolol and experimental atherosclerosis: atherosclerotic development and blood lipids during anabolic steroid therapy of New Zealand white rabbits. Scand J Clin Lab Invest 50:693-696
148. Obasanjo IO, Clarkson TB, Weaver DS 1996 Effects of the anabolic steroid nandrolone decanoate on plasma lipids and coronary arteries of female cynomolgus macaques. Metabolism 45:463-468
149. Adams MR, Williams JK, Kaplan JR 1995 Effects of androgens on coronary artery atherosclerosis and atherosclerosis-related impairment of vascular responsiveness. Arterioscler Thromb Vasc Biol 15:562-570
150. Bourassa PA, Milos PM, Gaynor BJ, Breslow JL, Aiello RJ 1996 Estrogen reduces atherosclerotic lesion development in apolipoprotein E-deficient mice. Proc Natl Acad Sci USA 93:10022-10027
151. Elhage R, Bayard F, Holvoet P, Duverger N, Fievet C, Arnal JF 1997 Prevention of fatty streak formation of 17β-estradiol is not mediated by the production of nitric oxide in apolipoprotein-E deficient mice. Circulation 96:3048-3052
152. Elhage R, Arnal JF, Pieraggi MT, Duverger N, Fievet C, Faye JC, Bayard F 1997 17β-Estradiol prevents fatty streak formation in apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol 17:2679-2684
153. Zygmunt M, Herr F, Keller-Schoenwetter S, Kunzi-Rapp K, Munstedt K, Rao CV, Lang U, Preissner KT 2002 Characterization of human chorionic gonadotropin as a novel angiogenic factor. J Clin Endocrinol Metab 87:5290-5296
154. Lin AL, Schultz JJ, Brenner RM, Shain SA 1990 Sexual dimorphism characterizes baboon myocardial androgen receptors but not myocardial estrogen and progesterone receptors. J Steroid Biochem Mol Biol 37:85-95
155. Lin AL, Gonzalez Jr R, Shain SA 1985 Androgen directs apparent cytoplasmic and nuclear distribution of rat cardiovascular androgen receptors. Arteriosclerosis 5:659-667
156. Lin AL, Shain SA 1986 Sexual dimorphism characterizes steroid hormone modulation of rat aortic steroid hormone receptors. Endocrinology 119:296-302
157. Lin AL, Gonzalez Jr R, Carey KD, Shain SA 1987 Gender and baboon aortic steroid hormone receptors. Arteriosclerosis 7:248-255
158. Tamaya T, Misao R, Nakagawa M, Itoh T, Wada K, Fujimoto J, Imai A 1993 Estrogen and androgen receptors in aorta of the rabbit and regulation by estrogen and androgen. Res Commun Chem Pathol Pharmacol 82:3-11
159. Knauthe R, Diel P, Hegele-Hartung C, Engelhaupt A, Fritzemeier KH 1996 Sexual dimorphism of steroid hormone receptor messenger ribonucleic acid expression and hormonal regulation in rat vascular tissue. Endocrinology 137:3220-3227
160. Higashiura K, Mathur RS, Halushka PV 1997 Gender-related differences in androgen regulation of thromboxane A2 receptors in rat aortic smooth-muscle cells. J Cardiovasc Pharmacol 29:311-315
161. McCrohon JA, Death AK, Nakhla S, Jessup W, Handelsman DJ, Stanley KK, Celermajer DS 2000 Androgen receptor expression is greater in macrophages from male than from female donors. A sex difference with implications for atherogenesis. Circulation 101:224-226
162. Cutolo M, Accardo S, Villaggio B, Barone A, Sulli A, Coviello DA, Carabbio C, Felli L, Miceli D, Farruggio R, Carruba G, Castagnetta L 1996 Androgen and estrogen receptors are present in primary cultures of human synovial macrophages. J Clin Endocrinol Metab 81:820-827
163. Death AK, McGrath KCY, Gaus K, Williams P, Handelsman DJ, Celermajer DS, Testosterone signalling through surface receptors in human endothelial cells: potential implications for nongenomic effects of testosterone on vessel walls (abstract). Program of the 51st Annual Scientific Meeting of the Cardiac Society of Australia and New Zealand, Adelaide, Australia, 2003 (Abstract)
164. Tindall DJ 2000 Androgen receptors in prostate and skeletal muscle. Mayo Clin Proc 75(Suppl):S26-S30; discussion S30-S31
165. Hanke H, Lenz C, Hess B, Spindler KD, Weidemann W 2001 Effect of testosterone on plaque development and androgen receptor expression in the arterial vessel wall. Circulation 103:1382-1385
166. Libby P 2001 Current concepts of the pathogenesis of the acute coronary syndromes. Circulation 104:365-372
167. Ross R 1999 Atherosclerosis - an inflammatory disease. N Engl J Med 340:115-126
168. McCrohon JA, Jessup w, Handelsman DJ, Celermajer DS 1999 Androgen exposure increases human monocyte adhesion to vascular endothelium and endothelial cell expression of vascular cell adhesion molecule-1. Circulation 99:2317-2322
169. McGrath KCY, Sader MS, Nakhla S, Jessup W, Handelsman DJ, Celermajer DS, Death AK, Androgens up-regulate VCAM-1 in a gender specific manner via a NFκβ-dependent pathway in human endothelial cells. Program of the 51st Annual Scientific Meeting of the Cardiac Society of Australia and New Zealand, Adelaide, Australia, 2003 (Abstract)
170. Zhang X, Wang LY, Jiang TY, Zhang HP, Dou Y, Zhao JH, Zhao H, Qiao ZD, Qiao JT 2002 Effects of testosterone and 17-β-estradiol on TNF-α-induced E-selectin and VCAM-1 expression in endothelial cells. Analysis of the underlying receptor pathways. Life Sci 71:15-29
171. Hatakeyama H, Nishizawa M, Nakagawa A, Nakano S, Kigoshi T, Uchida K 2002 Testosterone inhibits tumor necrosis factor-α-induced vascular cell adhesion molecule-1 expression in human aortic endothelial cells. FEBS Lett 530:129-132
172. Mukherjee TK, Dinh H, Chaudhuri G, Nathan L 2002 Testosterone attenuates expression of vascular cell adhesion molecule-1 by conversion to estradiol by aromatase in endothelial cells: implications in atherosclerosis. Proc Natl Acad Sci USA 99:4055-4060
173. Bombeli T, Schwartz BR, Harlan JM 1999 Endothelial cells undergoing apoptosis become proadhesive for nonactivated platelets. Blood 93:3831-3838
174. Ling S, Dai A, Williams MR, Myles K, Dilley RJ, Komesaroff PA, Sudhir K 2002 Testosterone (T) enhances apoptosis-related damage in human vascular endothelial cells Endocrinology 143:1119-1125
175. Kolodgie FD, Jacob A, Wilson PS, Carlson GC, Farb A, Verma A, Virmani R 1996 Estradiol attenuates directed migration of vascular smooth muscle cells in vitro. Am J Pathol 148:969-976
176. Akishita M, Ouchi Y, Miyoshi H, Kozaki K, Inoue S, Ishikawa M, Eto M, Toba K, Orimo H 1997 Estrogen inhibits cuff-induced intimal thickening of rat femoral artery: effects on migration and proliferation of vascular smooth muscle cells. Atherosclerosis 130:1-10
177. Chen SJ, Li H, Durand J, Oparil S, Chen YF 1996 Estrogen reduces myointimal proliferation after balloon injury of rat carotid artery. Circulation 93:577-584
178. Langer C, Gansz B, Goepfert C, Engel T, Uehara Y, von Dehn G, Jansen H, Assmann G, von Eckardstein A 2002 Testosterone upregulates scavenger receptor BI and stimulates cholesterol efflux from macrophages. Biochem Biophys Res Commun 296:1051-1057
179. Fluiter K, van der Westhuijzen DR, van Berkel TJ 1998 In vivo regulation of scavenger receptor BI and the selective uptake of high density lipoprotein cholesteryl esters in rat liver parenchymal and Kupffer cells. J Biol Chem 273:8434-8438
180. Eriedl R, Brunner M, Moeslinger T, Spieckermann PG 2000 Testosterone inhibits expression of inducible nitric oxide synthase in murine macrophages. Life Sci 68:417-429
181. Benten PM, Lieberherr M, Stamm O, Werehlke C, Guo Z, Wunderlich F 1999 Testosterone signaling through internalizable surface receptors in androgen receptor-free macrophages. Mol Biol Cell 10:393-397
182. Guo Z, Benten PM, Krucken J, Wunderlich F 2002 Nongenomic testosterone calcium signaling-genotropic actions in androgen receptor-free macrophages. J Biol Chem 277:29600-29607
183. Rubio-Gayosso I, Garcia-Ramirez O, Gutierrez-Serdan R, Guevara-Balcazar M, Munoz-Garcia O, Morato-Cartajena T, Zamora-Garza M, Ceballos-Reyes G 2002 Testosterone inhibits bradykinin-induced intracellular calcium kinetics in rat aortic endothelial cells in culture. Steroids 67:393-397
184. Lieberherr M, Grosse B 1994 Androgens increase intracellular calcium concentration and inositol 1,4,5-trisphosphate and diacylglycerol formation via a pertussis toxin-sensitive G-protein. J Biol Chem 269:7217-7223
185. Turner HH 1950 The clinical use of testosterone. Springfield, IL: Charles C. Thomas; 17
186. Costarella CE, Stallone JN, Rutecki GW, Whittier FC 1996 Testosterone causes direct relaxation of rat thoracic aorta. J Pharmacol Exp Ther 277:34-39
187. 2+ entry mechanisms of arterial vasoconstriction by sex hormones. Clin Exp Pharmacol Physiol 26:707-715
188. 2+ channels in the vasodilating effect of 5β-dihydrotestosterone in rat aorta. Eur J Pharmacol 371:169-178
189. + channel activation. J Appl Physiol 91:2742-2750
190. Tep-areenan P, Kendall DA, Randall MD 2002 Testosterone-induced vasorelaxation in the rat mesenteric arterial bed is mediated predominantly via potassium channels. Br J Pharmacol 135:735-740
191. Jones RD, Pugh PJ, Hall J, Channer KS, Jones TH 2003 Altered circulating hormone levels, endothelial function and vascular reactivity in the testicular feminised mouse. Eur J Endocrinol 148:111-120
192. Yue P, Chatterjee K, Beale C, Poole-Wilson PA, Collins P 1995 Testosterone relaxes rabbit coronary arteries and aorta. Circulation 91:1154-1160
193. 2+ entry mechanisms of coronary vasoconstriction. Arterioscler Thromb Vasc Biol 19:1034-1040
194. Deenadayalu VP, White RE, Stallone JN, Gao X, Garcia AJ 2001 Testosterone relaxes coronary arteries by opening the large-conductance, calcium-activated potassium channel. Am J Physiol Heart Circ Physiol 281:H1720-H1727
195. Schror K, Morinelli TA, Masuda A, Matsuda K, Mathur RS, Halushka PV 1994 Testosterone treatment enhances thromboxane A2 mimetic induced coronary artery vasoconstriction in guinea pigs. Eur J Clin Invest 24(Suppl 1):50-52
196. +-channel opener. Am J Physiol 274:L186-L195
197. Chou TM, Sudhir K, Hutchinson SJ, Ko E, Amidon TM, Collins P, Chatterjee K 1996 Testosterone induces dilatation of canine coronary conductance and resistance arteries in vivo. Circulation 94:2614-2619
198. Stallone JN, Salisbury RL, Fulton CT 2001 Androgen-receptor defect abolishes sex differences in nitric oxide and reactivity to vasopressin in rat aorta. J Appl Physiol 91:2602-2610
199. Ceballos G, Figueroa L, Rubio I, Gallo G, Garcia A, Martinez A, Yanez R, Perez J, Morato T, Chamorro G 1999 Acute and nongenomic effects of testosterone on isolated and perfused rat heart. J Cardiovasc Pharmacol 33:691-697
200. Figueroa-Valverde L, Luna H, Castillo-Henkel C, Munoz-Garcia O, Morato-Cartagena T, Ceballos-Reyes G 2002 Synthesis and evaluation of the cardiovascular effects of two, membrane impermeant, macromolecular complexes of dextran-testosterone. Steroids 67:611-619
201. Teoh H, Quan A, Man RY 2000 Acute impairment of relaxation by low levels of testosterone in porcine coronary arteries. Cardiovasc Res 45:1010-1018
202. Jones RD, English KM, Pugh PJ, Morice AH, Jones TH, Channer KS 2002 Pulmonary vasodilatory action of testosterone: evidence of a calcium antagonistic action J Cardiovasc Pharmacol 39:814-823
203. Murphy JG, Khalil RA 1999 Decreased [Ca(2+)](i) during inhibition of coronary smooth muscle contraction by 17β-estradiol, progesterone, and testosterone. J Pharmacol Exp Ther 291:44-52
204. English KM, Jones RD, Jones TH, Morice AH, Channer KS 2002 Testosterone acts as a coronary vasodilator by a calcium antagonistic action. J Endocrinol Invest 25:455-458
205. + channels of hypoxic human pulmonary vascular cells. Am J Respir Cell Mol Biol 20:737-745
206. Molinari C, Battaglia A, Grossini E, Mary DA, Vassanelli C, Vacca G 2002 The effect of testosterone on regional blood flow in prepubertal anaesthetized pigs. J Physiol 543:365-372
207. Ferrer M, Encabo A, Marin J, Balfagon G 1994 Treatment with the anabolic steroid, nandrolone, reduces vasoconstrictor responses in rabbit arteries. Eur J Pharmacol 258:103-110
208. English KM, Jones RD, Jones TH, Morice AH, Channer KS 2001 Gender differences in the vasomotor effects of different steroid hormones in rat pulmonary and coronary arteries. Horm Metab Res 33:645-652
209. English KM, Jones RD, Jones TH, Morice AH, Channer KS 2000 Aging reduces the responsiveness of coronary arteries from male Wistar rats to the vasodilatory action of testosterone. Clin Sci (Lond) 99:77-82
210. Bhargava KP, Dhawan KN, Saxena RC 1967 Enhancement of noradrenaline pressor responses in testosterone-treated cats. Br J Pharmacol 31:26-31
211. Greenberg S, Heitz DC, Long JP 1973 Testosterone-induced depression of adrenergic activity in the perfused canine hindlimb. Proc Soc Exp Biol Med 142:883-888
212. Greenberg S, George WR, Kadowitz PJ, Wilson WR 1974 Androgen-induced enhancement of vascular reactivity. Can J Physiol Pharmacol 52:14-22
213. Ferrer M, Encabo A, Marin J, Balfagon G 1994 Chronic treatment with the anabolic steroid, nandrolone, inhibits vasodilator responses in rabbit aorta. Eur J Pharmacol 252:233-241
214. Sader MA, Celermajer DS 2002 Endothelial function, vascular reactivity and gender differences in the cardiovascular system. Cardiovasc Res 53:597-604
215. Ludmer PL, Selwyn AP, Shook TL, Wayne RR, Mudge GH, Alexander RW, Ganz P 1986 Paradoxical vasoconstriction induced by acetylcholine in atherosclerotic coronary arteries. N Engl J Med 315:1046-1051
216. Celermajer DS, Sorensen KE, Gooch VM, Spiegelhalter DJ, Miller OI, Sullivan ID, Lloyd JK, Deanfield JE 1992 Non-invasive detection of endothelial dysfunction in children and adults at risk of atherosclerosis. Lancet 340:1111-1115
217. Raitakari OT, Celermajer DS 2000 Flow-mediated dilatation. Br J Clin Pharmacol 50:397-404
218. Hashimoto M, Akishita M, Eto M, Ishikawa M, Kozaki K, Toba K, Sagara Y, Taketani Y, Orimo H, Ouchi Y 1995 Modulation of endothelium-dependent flow-mediated dilatation of the brachial artery by sex and menstrual cycle. Circulation 92:3431-3435
219. Simons LA, von Konigsmark M, Simons J, Stocker R, Celermajer DS 1999 Vitamin E ingestion does not improve arterial endothelial dysfunction in older adults. Atherosclerosis 143:193-199
220. Celermajer DS, Sorensen KE, Spiegelhalter DJ, Georgakopoulos D, Robinson J, Deanfield JE 1994 Aging is associated with endothelial dysfunction in healthy men years before the age-related decline in women. J Am Coll Cardiol 24:471-476
221. Herman SM, Robinson JT, McCredie RJ, Adams MR, Boyer MJ, Celermajer DS 1997 Androgen deprivation is associated with enhanced endothelium-dependent dilatation in adult men. Arterioscler Thromb Vasc Biol 17:2004-2009
222. Zitzmann M, Brune M, Nieschlag E 2002 Vascular reactivity in hypogonadal men is reduced by androgen substitution. J Clin Endocrinol Metab 87:5030-5037
223. Clarke SC, Schofield PM, Grace AA, Metcalfe JC, Kirschenlohr HL 2001 Tamoxifen effects on endothelial function and cardiovascular risk factors in men with advanced atherosclerosis. Circulation 103:1497-502
224. Ong PJ, Patrizi G, Chong WC, Webb CM, Hayward CS, Collins P 2000 Testosterone enhances flow-mediated brachial artery reactivity in men with coronary artery disease. Am J Cardiol 85:269-272
225. Kang SM, Jang Y, Kim JY, Chung N, Cho SY, Chae JS, Lee JH 2002 Effect of oral administration of testosterone on brachial arterial vasoreactivity in men with coronary artery disease. Am J Cardiol 89:862-864
226. Sader MA, Griffiths KA, McCredie RJ, Handelsman DJ, Celermajer DS 2001 Androgenic anabolic steroids and arterial structure and function in male bodybuilders. J Am Coll Cardiol 37:224-230
227. Ebenbichler CF, Sturm W, Ganzer H, Bodner J, Mangweth B, Ritsch A, Sandhofer A, Lechleitner M, Foger B, Patsch JR 2001 Flow-mediated, endothelium-dependent vasodilatation is impaired in male body builders taking anabolic-androgenic steroids. Atherosclerosis 158:483-490
228. Kenny AM, Prestwood KM, Gruman CA, Fabregas G, Biskup B, Mansoor G 2002 Effects of transdermal testosterone on lipids and vascular reactivity in older men with low bioavailable testosterone levels. J Gerontol A Biol Sci Med Sci 57:M460-M465
229. Liu PY, Wishart SM, Celermajer DS, Jimenez M, Pierro ID, Conway AJ, Handelsman DJ 2003 Do reproductive hormones modify insulin sensitivity and metabolism in older men? A randomized, placebo-controlled clinical trial of recombinant human chorionic gonadotropin. Eur J Endocrinol 148:55-66
230. Ly LP, Jimenez M, Zhuang TN, Celermajer DS, Conway AJ, Handelsman DJ 2001 A double-blind, placebo-controlled, randomized clinical trial of transdermal dihydrotestosterone gel on muscular strength, mobility, and quality of life in older men with partial androgen deficiency. J Clin Endocrinol Metab 86:4078-4088
231. McCrohon JA, Walters WA, Robinson JTC, McCredie RJ, Turner L, Adams MR, Handelsman DJ, Celermajer DS 1997 Arterial reactivity is enhanced in genetic males taking high dose estrogens. J Am Coll Cardiol 29:1432-1436
232. New G, Timmins KL, Duffy SJ, Tran BT, O'Brien RC, Harper RW, Meredith IT 1997 Long-term estrogen therapy improves vascular function in male to female transsexuals. J Am Coll Cardiol 29:1437-1444
233. New G, Duffy SJ, Harper RW, Meredith IT 2000 Long-term oestrogen therapy is associated with improved endothelium-dependent vasodilation in the forearm resistance circulation of biological males. Ciln Exp Pharmacol Physiol 27:25-33
234. Komesaroff PA, Fullerton M, Esler MD, Dart A, Jennings G, Sudhir K 2001 Low-dose estrogen supplementation improves vascular function in hypogonadal men. Hypertension 38:1011-1016
235. Sader MA, McCredie RJ, Griffiths KA, Wishart SM, Handelsman DJ, Celermajer DS 2001 Oestradiol improves arterial endothelial function in healthy men receiving testosterone. Clin Endocrinol (Oxf) 54:175-181
236. New G, Duffy SJ, Berry KL, Harper RW, Meredith IT 1999 Acute administration of 17β-oestradiol does not improve endothelium-dependent vasodilatation in young men. Clin Sci (Lond) 97:225-232
237. Sudhir K, Chou TM, Messina LM, Hutchison SJ, Korach KS, Chatterjee K, Rubanyi GM 1997 Endothelial dysfunction in a man with disruptive mutation in oestrogen-receptor gene. Lancet 349:1146-1147
238. McCredie RJ, McCrohon JA, Turner L, Griffiths KA, Handelsman DJ, Celermajer DS 1998 Vascular reactivity is impaired in genetic females taking high dose androgens. J Am Coll Cardiol 32:1331-1335
239. Worboys S, Kotsopoulos D, Teede H, McGrath B, Davis SR 2001 Evidence that parenteral testosterone therapy may improve endothelium-dependent and -independent vasodilation in postmenopausal women already receiving estrogen. J Clin Endocrinol Metab 86:158-161
240. Alexandersen P, Haarbo J, Christiansen C 1996 The relationship of natural androgens to coronary heart disease in male: a review. Atherosclerosis 125:1-13
241. English KM, Steeds R, Jones TH, Channer KS 1997 Testosterone and coronary heart disease: is there a link? QJM 90:787-791
242. Wu FCW, von Eckardstein A 2002 Androgen and coronary artery disease. In: McLachlan RI, ed. Male reproductive endocrinology, Endotext.com, Chap. 16 (web version of Endocrinology, 4th ed.). www.endotext.org
243. Barrett-Connor EL 1995 Testosterone and risk factors for cardiovascular disease in men. Diabetes Metab 21:156-161
244. Barrett-Connor E 1996 Testosterone, HDL-cholesterol and cardiovascular disease. In: Bhasin S, Gabelnick HL, Spieler JM, Swerdloff RS, Wang C, Kelly C, eds. Pharmacology, biology, and clinical applications of androgens: current status and future prospects. New York: Wiley-Liss; 215-223
245. English KM, Mandour O, Steeds RP, Diver MJ, Jones TH, Channer KS 2000 Men with coronary artery disease have lower levels of androgens than men with normal coronary angiograms. Eur Heart J 21:890-894
246. Hak AE, Witteman JC, De Jong FH, Geerlings MI, Hofman A, Pols HA 2002 Low levels of endogenous androgens increase the risk of atherosclerosis in elderly men: the Rotterdam study. J Clin Endocrinol Metab 87:3632-3639
247. Woolf PD, Hamill RW, McDonald JV, Lee LA, Kelly M 1985 Transient hypogonadotropic hypogonadism caused by critical illness. J Clin Endocrinol Metab 60:444-450
248. Semple CG, Gray CE, Beastall GH 1987 Male hypogonadism: a non-specific consequence of illness. Q J Med 64:601-607
249. Gray A, Feldman HA, McKinlay JB, Longcope C 1991 Age, disease, and changing sex hormone levels in middle-aged men: results of the Massachusetts Male Aging Study. J Clin Endocrinol Metab 73:1016-1025
250. Handelsman DJ 1997 Testicular dysfunction in systemic diseases. In: Nieschlag E, Behre HM, eds. Andrology: male reproductive health and dysfunction. Berlin: Springer-Verlag; 227-237
251. Barrett-Connor E, Khaw KT 1988 Endogenous sex hormones and cardiovascular disease in men. A prospective population-based study. Circulation 78:539-545
252. Feldman HA, Johannes CB, Araujo AB, Mohr BA, Longcope C, McKinlay JB 2001 Low dehydroepiandrosterone and ischemic heart disease in middle-aged men: prospective results from the Massachusetts Male Aging Study. Am J Epidemiol 153:79-89
253. Barrett-Connor E, Khaw KT, Yen SS 1986 A prospective study of dehydroepiandrosterone sulfate, mortality, and cardiovascular disease. N Engl J Med 315:1519-1524
254. Contoreggi CS, Blackman MR, Andres R, Muller DC, Lakatta EG, Fleg JL, Harman SM 1990 Plasma levels of estradiol, testosterone, and DHEAS db not predict risk of coronary artery disease in men. J Androl 11:460-470
255. LaCroix AZ, Yano K, Reed DM 1992 Dehydroepiandrosterone sulfate, incidence of myocardial infarction, and extent of atherosclerosis in men. Circulation 86:1529-1535
256. Newcomer LM, Manson JE, Barbieri RL, Hennekens CH, Stampfer MJ 1994 Dehydroepiandrosterone sulfate and the risk of myocardial infarction in US male physicians: a prospective study. Am J Epidemiol 140:870-875
257. Barrett-Connor E, Goodman-Gruen D 1995 The epidemiology of DHEAS and cardiovascular disease. Ann NY Acad Sci 774:259-270
258. Meikle AW, Dorchuck RW, Araneo BA, Stringham JD, Evans TG, Spruance SL, Daynes RA 1992 The presence of a dehydroepiandrosterone-specific receptor binding complex in murine T cells. J Steroid Biochem Mol Biol 42:293-304
259. Okabe T, Haji M, Takayanagi R, Adachi M, Imasaki K, Kurimoto F, Watanabe T, Nawata H 1995 Up-regulation of high-affinity dehydroepiandrosterone binding activity by dehydroepiandrosterone in activated human T lymphocytes. J Clin Endocrinol Metab 80:2993-2996
260. Tsuji K, Furutama D, Tagami M, Ohsawa N 1999 Specific binding and effects of dehydroepiandrosterone sulfate (DHEA-S) on skeletal muscle cells: possible implication for DHEA-S replacement therapy in patients with myotonic dystrophy. Life Sci 65:17-26
261. Willson TM, Moore JT 2002 Genomics vs. orphan nuclear receptors - a half-time report. Mol Endocrinol 16:1135-1144
262. Baulieu EE, Robel P, Schumacher M 2001 Neurosteroids: beginning of the story. Int Rev Neurobiol 46:1-32
263. Gupte SA, Li KX, Okada T, Sato K, Oka M 2002 Inhibitors of pentose phosphate pathway cause vasodilation: involvement of voltage-gated potassium charmels. J Pharmacol Exp Ther 301:299-305
264. Svec F, Porter JR 1998 The actions of exogenous dehydroepiandrosterone in experimental animals and humans. Proc Soc Exp Biol Med 218:174-191
265. Jansson JHH, Nilsson TK, Johnson O 1998 von Willebrand factor, tissue plasminogen activator, and dehydroepiandrosterone sulphate predict cardiovascular death in a 10 year follow up of survivors of acute myocardial infarction. Heart 80:334-337
266. Moriyama Y, Yasue H, Yoshimura M, Mizuno Y, Nishiyama K, Tsunoda R, Kawano H, Kugiyama K, Ogawa H, Saito Y, Nakao K 2000 The plasma levels of dehydroepiandrosterone sulfate are decreased in patients with chronic heart failure in proportion to the severity. J Clin Endocrinol Metab 85:1834-1840
267. Walker TC 1942 Use of testosterone propionate and estrogenic substance in treatment of essential hypertension, angina pectoris and peripheral vascular disease. J Clin Endocrinol 2:560-568
268. Sigler LH, Tulgan J 1943 Treatment of angina pectoris by testosterone propionate. NY State J Med 43:1424-1428
269. Lesser MA 1946 Testosterone propionate therapy in one hundred cases of angina pectoris. J Clin Endocrinol Metab 6:549-557
270. Kochakian CD 1976 Anabolic-androgenic steroids. Berlin: Springer-Verlag
271. Jaffe MD 1977 Effect of testosterone cypionate on postexercise ST segment depression. Br Heart J 39:1217-1222
272. Wu S, Weng X 1993 Therapeutic effects of an androgenic preparation on myocardial ischemia and cardiac function in 62 elderly male coronary heart disease patients. Chin Med J (Engl) 106:415-418
273. Wu S, Weng X 1992 Therapeutic effects of andriol on serum lipids and apolipoproteins in elderly male coronary heart disease patients Chin Med Sci J 7:137-141
274. English KM, Steeds RP, Jones TH, Diver MJ, Channer KS 2000 Low-dose transdermal testosterone therapy improves angina threshold in men with chronic stable angina: a randomized, double-blind, placebo-controlled study. Circulation 102:1906-1911
275. Webb CM, Adamson DL, de Zeigler D, Collins P 1999 Effect of acute testosterone on myocardial ischemia in men with coronary artery disease. Am J Cardiol 83:437-439; A9
276. Rosano GMC, Leonardo F, Pagnotta P, Pelliccia F, Panina G, Cerquetani E, della Monica PL, Bonfigli B, Volpe M, Chierchia SL 1999 Acute anti-ischemic effect of testosterone in men with coronary artery disease. Circulation 99:1666-1670
277. Thompson PD, Ahlberg AW, Moyna NM, Duncan B, Ferraro-Borgida M, White CM, McGill CC, Heller GV 2002 Effect of intravenous testosterone on myocardial ischemia in men with coronary artery disease. Am Heart J 143:249-256
278. Webb CM, McNeill JG, Hayward CS, de Zeigler D, Collins P 1999 Effects of testosterone on coronary vasomotor regulation in men with coronary heart disease. Circulation 100:1690-1696
279. Reckelhoff JF 2001 Gender differences in the regulation of blood pressure. Hypertension 37:1199-1208
280. Dubey RK, Oparil S, Imthum B, Jackson EK 2002 Sex hormones and hypertension. Cardiovasc Res 53:688-708
281. Staessen J, Fagard R, Lijnen P, Thijs L, van Hoof R, Amery A 1990 Reference values for ambulatory blood pressure: a meta-analysis. J Hypertens Supp1 8:S57-S64
282. Burt VL, Whelton P, Roccella EJ, Brown C, Cutler JA, Higgins M, Horan MJ, Labarthe D 1995 Prevalence of hypertension in the US adult population. Results from the Third National Health and Nutrition Examination Survey, 1988-1991. Hypertension 25:305-313
283. Dockery F, Rajkumar C, Agarwal S, Waxman J, Bulpitt CJ 2000 Androgen deprivation in males is associated with decreased central arterial compliance and reduced central systolic blood pressure. J Hum Hypertens 14:395-397
284. Smith JC, Bennett S, Evans LM, Kynaston HG, Parmar M, Mason MD, Cockcroft JR, Scanlon MF, Davies JS 2001 The effects of
285. Henriksson P, Linde B 1994 Deteriorated arterial supply to the lower limb during oral oestrogen therapy of patients with prostatic carcinoma. Urol Lnt 53:74-78
286. Khaw KT, Barrett-Connor E 1988 Blood pressure and endogenous testosterone in men: an inverse relationship. J Hypertens 6:329-332
287. Gray A, Berlin JA, McKinlay JB, Longcope C 1991 An examination of research design effects on the association of testosterone and male aging: results of a meta-analysis. J Clin Epidemiol 144:671-684
288. Fogari R, Zoppi A, Preti P, Rinaldi A, Marasi G, Vanasia A, Mugellini A 2002 Sexual activity and plasma testosterone levels in hypertensive males. Am J Hypertens 15:217-221
289. Hughes GS, Mathur RS, Margolius HS 1989 Sex steroid hormones are altered in essential hypertension. J Hypertens 7:181-187
290. Phillips GB, Jing TY, Resnick LM, Barbagallo M, Laragh JH, Sealey JE 1993 Sex hormones and hemostatic risk factors for coronary heart disease in men with hypertension. J Hypertens 11:699-702
291. Jaffe A, Chen Y, Kisch ES, Fischel B, Alon M, Stern N 1996 Erectile dysfunction in hypertensive subjects. Assessment of potential determinants. Hypertension 28:859-862
292. Rosen RC 1997 Sexual dysftmction as an obstacle to compliance with antihypertensive therapy. Blood Press Suppl 1:47-51
293. Jensen J, Lendorf A, Stimpel H, Frost J, Ibsen H, Rosenkilde P 1999 The prevalence and etiology of impotence in 101 male hypertensive outpatients. Am J Hypertens 12:271-275
294. Suzuki H, Tominaga T, Kumagai H, Saruta T 1988 Effects of first-line antihypertensive agents on sexual ftmction and sex hormones. J Hypertens 6:S649-S651
295. Fogari R, Preti P, Derosa G, Marasi G, Zoppi A, Rinaldi A, Mugellini A 2002 Effect of antihypertensive treatment with valsartan or atenolol on sexual activity and plasma testosterone in hypertensive men. Eur J Clin Pharmacol 58:177-180
296. Jannini EA, Screponi E, Carosa E, Pepe M, Lo Giudice F, Trimarchi F, Benvenga S 1999 Lack of sexual activity from erectile dysfunction is associated with a reversible reduction in serum testosterone. Int J Androl 22:385-392
297. Reckelhoff JF, Zhang H, Srivastava K, Granger JP 1999 Gender differences in hypertension in spontaneously hypertensive rats: role of androgens and androgen receptor. Hypertension 34:920-923
298. Cambotti LJ, Cole FE, Gerall AA, Frohlich ED, MacPhee AA 1984 Neonatal gonadal hormones and blood pressure in the spontaneously hypertensive rat. Am J Physiol 247:E258-E264
299. Reckelhoff JF, Zhang H, Srivastava K 2000 Gender differences in development of hypertension in spontaneously hypertensive rats: role of the renin-angiotensin system. Hypertension 35:480-483
300. Jin B, Beilin J, Zajac J, Handelsman DJ 2000 Androgen receptor gene polymorphism and prostate zonal volumes in Australian and Chinese men. J Androl 21:91-98
301. Khalid M, Ilhami N, Giudicelli Y, Dausse JP 2002 Testosterone dependence of salt-induced hypertension in Sabra rats and role of renal α(2)-adrenoceptor subtypes. J Pharmacol Exp Ther 300:43-49
302. Ely D, Caplea A, Dunphy G, Daneshvar H, Turner M, Milsted A, Takiyyudin M 1997 Spontaneously hypertensive rat Y chromosome increases indexes of sympathetic nervous system activity. Hypertension 29:613-618
303. Schmalbach NL, Kutscher CL 1976 Testosterone and the sex difference in blood pressure in mice. Pharmacol Biochem Behav 4:339-341
304. Lim YK, Retnam L, Bhagavath B, Sethi SK, bin Ali A, Lim SK 2002 Gonadal effects on plasma ACE activity in mice. Atherosclerosis 160:311-316
305. Freshour JR, Chase SE, Vikstrom KL 2002 Gender differences in cardiac ACE expression are normalized in androgen-deprived male mice. Am J Physiol Heart Circ Physiol 283:H1997-H2003
306. Cvetkovic B, Sigmund CD 2000 Understanding hypertension through genetic manipulation in mice. Kidney Int 57:863-874
307. Sigmund CD 2001 Genetic manipulation of the renin-angiotensin system: targeted expression of the renin-angiotensin system in the kidney. Am J Hypertens 14:33S-37S
308. Hayward CS, Kelly RP, Collins P 2000 The roles of gender, the menopause and hormone replacement on cardiovascular function. Cardiovasc Res 46:28-49
309. Hayward CS, Webb CM, Collins P 2001 Effect of sex hormones on cardiac mass. Lancet 357:1354-1356
310. Gardner JD, Brower GL, Janicki JS 2002 Gender differences in cardiac remodeling secondary to chronic volume overload. J Card Fail 8:101-107
311. Nahrendorf M, Frantz S, Hu K, von zur Muhlen C, Tomaszewski M, Scheuermann H, Kaiser R, Jazbutyte V, Beer S, Bauer W, Neubauer S, Ertl G, Allolio B, Callies F 2003 Effect of testosterone on post-myocardial infarction remodeling and function. Cardiovasc Res 57:370-378
312. Cavasin MA, Sankey SS, Yu AL, Menon S, Yang XP 2003 Estrogen and testosterone have opposing effects on chronic cardiac remodeling and function in mice with myocardial infarction. Am J Physiol Heart Circ Physiol 284:H1560-H1569
313. Thum T, Borlak J 2002 Testosterone, cytochrome P450, and cardiac hypertrophy. FASEB J 16:1537-1549
314. Takeishi Y, Walsh RA 2001 Cardiac hypertrophy and failure: lessons learned from genetically engineered mice. Acta Physiol Scand 173:103-111
315. Brouillette J, Trepanier-Boulay V, Fiset C 2003 Effect of androgen deficiency on mouse ventricular repolarization. J Physiol 546:403-413
316. Noirhomme P, Jacquet L, Underwood M, El Khoury G, Goenen M, Dion R 1999 The effect of chronic mechanical circulatory support on neuroendocrine activation in patients with end-stage heart failure. Eur J Cardiothorac Surg 16:63-67
317. Kontoleon PE, Anastasiou-Nana MI, Papapetrou PD, Alexopoulos G, Ktenas V, Rapti AC, Tsagalou EP, Nanas JN 2003 Hormonal profile in patients with congestive heart failure. Int J Cardiol 87:179-183
318. Anker SD, Chua TP, Ponikowski P, Harrington D, Swan JW, Kox WJ, Poole-Wilson PA, Coats AJ 1997 Hormonal changes and catabolic/anabolic imbalance in chronic heart failure and their importance for cardiac cachexia. Circulation 96:526-534
319. Kiilavuori K, Naveri H, Leinonen H, Harkonen M 1999 The effect of physical training on hormonal status and exertional hormonal response in patients with chronic congestive heart failure. Eur Heart J 20:456-464
320. Handelsman DJ, Dong Q 1992 Ontogenic regression: a model of stress and reproduction. In: Sheppard K, Boubiik JH, Funder JW, eds. Stress and reproduction. New York: Raven Press; 333-345
321. Pugh PJ, Jones RD, West JN, Channer KS, Jones TH, Testosterone therapy for men with chronic congestive heart failure. Program of the 84th Annual Meeting of The Endocrine Society, San Francisco, CA, 2002, p 144 (Abstract OR59-4)
322. Coats AJ 2002 Origin of symptoms in patients with cachexia with special reference to weakness and shortness of breath. Int J Cardiol 85:133-139
323. Young W, Gofman JW, Tandy R, Malamud N, Waters ESG 1960 The quantification of atherosclerosis. III. The extent of correlation of degrees of atherosclerosis within and between coronary, and cerebral vascular beds. Am J Cardiol 6:300-308
324. Solberg LA, Strong JP 1983 Risk factors and atherosclerotic lesions. A review of autopsy studies. Arteriosclerosis 3:187-198
325. Sorensen KE, Kristensen IB, Celermajer DS 1997 Atherosclerosis in the human brachial artery. J Am Coll Cardiol 29:318-322
326. Thubrikar MJ, Robicsek F 1995 Pressure-induced arterial wall stress and atherosclerosis. Ann Thorac Surg 59:1594-1603
327. Drouet L 2002 Atherothrombosis as a systemic disease. Cerebrovasc Dis 13(Suppl 1):1-6
328. Simons PC, Algra A, Bots ML, Banga JD, Grobbee DE, van der Graaf Y 1999 Common carotid intima-media thickness in patients with peripheral arterial disease or abdominal aortic aneurysm: the SMART study. Second Manifestations of ARTerial disease. Atherosclerosis 146:243-248
329. Thorvaldsen P, Asplund K, Kuulasmaa K, Rajakangas AM, Schroll M 1995 Stroke incidence, case fatality, and mortality in the WHO MONICA project. World Health Organization Monitoring Trends and Determinants in Cardiovascular Disease. Stroke 26:361-367
330. Sudlow CL, Warlow CP 1997 Comparable studies of the incidence of stroke and its pathological types: results from an international collaboration. International Stroke Incidence Collaboration. Stroke 28:491-499
331. Sacco RL, Benjamin EJ, Broderick JP, Dyken M, Easton JD, Feinberg WM, Goldstein LB, Gorelick PB, Howard G, Kittner SJ, Manolio TA, Whisnant JP, Wolf PA 1997 American Heart Association Prevention Conference. IV. Prevention and Rehabilitation of Stroke. Risk factors. Stroke 28:1507-1517
332. Brown RD, Whisnant JP, Sicks JD, O'Fallon WM, Wiebers DO 1996 Stroke incidence, prevalence, and survival: secular trends in Rochester, Minnesota, through 1989. Stroke 27:373-380
333. Thrift AG, Dewey HM, Macdonell RA, McNeil JJ, Donnan GA 2001 Incidence of the major stroke subtypes: initial findings from the North East Melbourne stroke incidence study (NEMESIS). Stroke 32:1732-1738
334. Jeppesen LL, Jorgensen HS, Nakayama H, Raaschou HO, Skyhoj T, Winther K 1996 Decreased serum testosterone in men with acute ischemic stroke. Arterioscler Thromb Vasc Biol 16:749-754
335. Elwan O, Abdallah M, Issa I, Taher Y, el-Tamawy M 1990 Hormonal changes in cerebral infarction in the young and elderly. J Neurol Sci 98:235-243
336. Dash RJ, Sethi BK, Nalini K, Singh S 1991 Circulating testosterone in pure motor stroke. Funct Neurol 6:29-34
337. van den Beld AW, Bots ML, Janssen JA, Pols HA, Lamberts SW, Grobbee DE 2003 Endogenous hormones and carotid atherosclerosis in elderly men. Am J Epidemiol 157:25-31
338. O'Leary DH, Polak JF, Kronmal RA, Manolio TA, Burke GL, Wolfson Jr SK 1999 Carotid-artery intima and media thickness as a risk factor for myocardial infarction and stroke in older adults. Cardiovascular Health Study Collaborative Research Group. N Engl J Med 340:14-22
339. Friedl KE 1993 Effects of anabolic steroids on physical health. In: Yesalis CE, ed. Anabolic steroids in sports and exercise. Champaign, IL: Human Kinetics Publishers; 107-150
340. Akhter J, Hyder S, Ahmed M 1994 Cerebrovascular accident associated with anabolic steroid use in a young man. Neurology 44:2405-2406
341. Jaillard AS, Hommel M, Mallaret M 1994 Venous sinus thrombosis associated with androgens in a healthy young man. Stroke 25:212-213
342. Palfi S, Ungurean A, Vecsei L 1997 Basilar artery occlusion associated with anabolic steroid abuse in a 17-year-old bodybuilder. Eur Neurol 37:190-191
343. Ebo DG, Bracke PG, De Clerck LS, Francx LM, Stevens WJ 1997 Anticardiolipin (aCL) antibodies in a patient with Behcet's syndrome with vena cava inferior thrombosis. Clin Rheumatol 16:96-98
344. Lisiewicz J, Fijalkowski P, Sankowski J 1999 [Ischemic cerebral stroke and anabolic steroids (case report)]. Neurol Neurochir Pol 32(Suppl 6):137-139
345. Nagelberg SB, Laue L, Loriaux DL, Liu L, Sherins RJ 1986 Cerebrovascular accident associated with testosterone therapy in a 21-year-old hypogonadal man. N Engl J Med 314:649-650
346. Penotti M, Sironi L, Cannata L, Vigano P, Casini A, Gabrielli L, Vignali M 2001 Effects of androgen supplementation of hormone replacement therapy on the vascular reactivity of cerebral arteries. Fertil Steril 76:235-240
347. Geary GG, Krause DN, Duckies SP 2000 Gonadal hormones affect diameter of male rat cerebral arteries through endothelium-dependent mechanisms. Am J Physiol Heart Circ Physiol 279:H610-H618
348. Yamori Y, Horie R, Sato M, Ohta K 1976 Proceedings: prophylactic trials for stroke in stroke-prone SHR: effect of sex hormones. Jpn Heart J 17:404-406
349. Green PS, Simpkins JW 2000 Neuroprotective effects of estrogens: potential mechanisms of action. Int J Dev Neurosci 18:347-358
350. Wise PM 2002 Estrogens and neuroprotection. Trends Endocrinol Metab 13:229-230
351. Toung TJ, Traystman RJ, Hum PD 1998 Estrogen-mediated neuroprotection after experiraental stroke in male rats. Stroke 29:1666-1670
352. Yu WH, Yu MC 1983 Acceleration of the regeneration of the crushed hypoglossal nerve by testosterone. Exp Neurol 80:349-360
353. Kujawa KA, Tanzer L, Jones KJ 1995 Inhibition of the accelerative effects of testosterone on hamster facial nerve regeneration by the antiandrogen flutamide. Exp Neurol 133:138-143
354. Hammond J, Le Q, Goodyer C, Gelfand M, Trifiro M, LeBlanc A 2001 Testosterone-mediated neuroprotection through the androgen receptor in human primary neurons. J Neurochem 77:1319-1326
355. Ahlbom E, Prins GS, Ceccatelli S 2001 Testosterone protects cerebellar granule cells from oxidative stress-induced cell death through a receptor mediated mechanism. Brain Res 892:255-262
356. Jones KJ, Brown TJ, Damaser M 2001 Neuroprotective effects of gonadal steroids on regenerating peripheral motoneurons. Brain Res Brain Res Rev 37:372-382
357. Azcoitia I, Sierra A, Veiga S, Honda S, Harada N, Garcia-Segura LM 2001 Brain aromatase is neuroprotective. J Neurobiol 47:318-329
358. Green PS, Yang SH, Simpkins JW 2000 Neuroprotective effects of phenolic A ring oestrogens. Novartis Found Symp 230:202-213; discussion, 213-220
359. Hawk T, Zhang YQ, Rajakumar G, Day AL, Simpkins JW 1998 Testosterone increases and estradiol decreases middle cerebral artery occlusion lesion size in male rats. Brain Res 796:296-298
360. Yang SH, Perez E, Cutright J, Liu R, He Z, Day AL, Simpkins JW 2002 Testosterone increases neurotoxicity of glutamate in vitro and ischemia-reperfusion injury in an animal model. J Appl Physiol 92:195-201
361. Dong Q, Hawker F, McWilliam D, Bangah M, Burger H, Handelsman DJ 1992 Circulating inhibin and testosterone levels in men with critical illness. Clin Endocrinol (Oxf) 36:399-404
362. Ba ZF, Wang P, Koo DJ, Ornan DA, Bland KI, Chaudry IH 2001 Attenuation of vascular endothelial dysfunction by testosterone receptor blockade after trauma and hemorrhagic shock. Arch Surg 136:1158-1163
363. Dormandy JA, Rutherford RB 2000 Management of peripheral arterial disease (PAD). TASC Working Group. TransAtlantic Inter-Society Concensus (TASC). J Vasc Surg 31:S1-S296
364. Hiatt WR 2001 Medical treatment of peripheral arterial disease and claudication. N Engl J Med 344:1608-1621
365. McDermott MM, Mehta S, Ahn H, Greenland P 1997 Atherosclerotic risk factors are less intensively treated in patients with peripheral arterial disease than in patients with coronary artery disease. J Gen Intern Med 12:209-215
366. Clark AL, Byrne JC, Nasser A, McGroarty E, Kennedy JA 1999 Cholesterol in peripheral vascular disease - a suitable case for treatment? QJM 92:219-222
367. Norman PE, Semmens JB, Lawrence-Brown M, Holman CD 2000 The influence of gender on outcome following peripheral vascular surgery: a review. Cardiovasc Surg 8:111-115
368. Meijer WT, Hoes AW, Rutgers D, Bots ML, Hofman A, Grobbee DE 1998 Peripheral arterial disease in the elderly: the Rotterdam study. Arterioscler Thromb Vasc Biol 18:185-192
369. Edwards EA, Hamilton JB, Duntley SQ 1939 Testosterone propionate as a therapeutic agent in patients with organic disease of the peripheral vessels. Preliminary report. N Engl J Med 220:865
370. Hamilton JB 1937 Treatment of sexual underdevelopment with synthetic male hormone substance. Endocrinology 21:649-654
371. Hentzer E, Madsen PC 1967 Testosterone in the treatment of arterial insufficiency of the lower limbs. Scand J Clin Lab Invest 99:198-206
372. Dohn K, Hvidt V, Nielsen J, Palm L 1968 Testosterone therapy in obliterating arterial lesions in the lower limbs. Angiology 19:342-350
373. Genster HG, Oram V 1971 Medical treatment of arterial insufficiency in the lower limbs. Ugeskr Laeger 133:244-246
374. Albrechtsen O, Barfod B, Barfod E, Laursen NP, Nordentoft B, Yde H 1972 Hormonal treatment of arterial insufficiency in the lower extremities. Dan Med Bull 19:157-159
375. Price JF, Leng GC 2002 Steroid sex hormones for lower limb atherosclerosis (Cochrane review). Cochrane database of systematic reviews. 4th ed. Oxford, UK: Update Software; 4
376. Simonsen U, Garcia-Sacristan A, Prieto D 2002 Penile arteries and erection. J Vasc Res 39:283-303
377. Rajfer J, Aronson WJ, Bush PA, Dorey FJ, Ignarro LJ 1992 Nitric oxide as a mediator of relaxation of the corpus cavernosum in response to nonadrenergic, noncholinergic neurotransmission. N Engl J Med 326:90-94
378. Gonzalez-Cadavid NF, Ignarro LJ, Rajfer J 1999 Nitric oxide and the cyclic GMP system in the penis. Mol Urol 3:51-59
379. Archer SL 2002 Potassium channels and erectile dysfunction. Vascul Pharmacol 38:61-71
380. Lue TF 2000 Erectile dysfunction. N Engl J Med 342:1802-1813
381. Goldstein I, Lue TF, Padma-Nathan H, Rosen RC, Steers WD, Wicker PA 1998 Oral sildenafil in the treatment of erectile dysfunction. Sildenafil Study Group. N Engl J Med 338:1397-1404
382. Corbin JD, Francis SH, Webb DJ 2002 Phosphodiesterase type 5 as a pharmacologic target in erectile dysfunction. Urology 60:4-11
383. Feldman HA, Goldstein I, Hatzichristou DG, Krane RJ, McKinlay JB 1994 Impotence and its medical and psychosocial correlates: results of the Massachusetts Male Aging Study. J Urol 151:54-61
384. Sullivan ME, Keoghane SR, Miller MA 2001 Vascular risk factors and erectile dysfunction. BJU Int 87:838-845
385. Azadzoi KM, Goldstein I 1992 Erectile dysfunction due to atherosclerotic vascular disease: the development of an animal model. J Urol 147:1675-1681
386. Adams MR, Kaplan JR, Koritnik DR, Weaver DS, Bond MG 1984 Erectile failure in cynomolgus monkeys with atherosclerosis of the arteries supplying the penis. J Urol 131:571-573
387. Thompson PD, Zimet R, Forbes WP, Zhang P 2002 Meta-analysis of results from eight randomized, placebo-controlled trials on the effect of cilostazol on patients with intermittent claudication. Am J Cardiol 90:1314-1319
388. Regensteiner JG, Ware Jr JE, McCarthy WJ, Zhang P, Forbes WP, Heckman J, Hiatt WR 2002 Effect of cilostazol on treadmill walking, community-based walking ability, and health-related quality of life in patients with intermittent claudication due to peripheral arterial disease: meta-analysis of six randomized controlled trials. J Am Geriatr Soc 50:1939-1946
389. Virag R, Bouilly P, Frydman D 1985 Is impotence an arterial disorder? A study of arterial risk factors in 440 impotent men. Lancet 1:181-184
390. Michal V 1982 Arterial disease as a cause of impotence. Clin Endocrinol Metab 11:725-748
391. Feldman HA, Johannes CB, Derby CA, Kleinman KP, Mohr BA, Araujo AB, McKinlay JB 2000 Erectile dysfunction and coronary risk factors: prospective results from the Massachusetts male aging study. Prev Med 30:328-338
392. Derby CA, Mohr BA, Goldstein I, Feldman HA, Johannes CB, McKinlay JB 2000 Modifiable risk factors and erectile dysfunction: can lifestyle changes modify risk? Urology 56:302-306
393. Jackson G 1997 Simvastatin and impotence. Br Med J 315:31
394. Pedersen TR, Faergeman O 1999 Simvastatin seems unlikely to cause impotence. BMJ 318:192
395. Rizvi K, Hampson JP, Harvey JN 2002 Do lipid-lowering drugs cause erectile dysfunction? A systematic review. Fam Pract 19:95-98
396. Bancroft J 1995 Are the effects of androgens on male sexuality noradrenergically mediated? Some consideration of the human. Neurosci Biobehav Rev 19:325-330
397. Wilson JD 1999 The role of androgens in male gender role behavior. Endocr Rev 20:726-737
398. Carani C, Granata AR, Bancroft J, Marrama P 1995 The effects of testosterone replacement on nocturnal penile tumescence and rigidity and erectile response to visual erotic stimuli in hypogonadal men. Psychoneuroendocrinology 20:743-753
399. Keast JR 2000 Effects of testosterone on pelvic autonomic pathways: progress and pitfalls. J Auton Nerv Syst 79:67-73
400. Shabsigh R 1997 The effects of testosterone on the cavernous tissue and erectile function. World J Urol 15:21-26
401. Melman A, Gingell JC 1999 The epidemiology and pathophysiology of erectile dysfunction. J Urol 161:5-11
402. Schiavi RC, White D, Mandeli J, Levine AC 1997 Effect of testosterone administration on sexual behavior and mood in men with erectile dysfunction. Arch Sex Behav 26:231-241
403. Sullivan ME, Thompson CS, Dashwood MR, Khan MA, Jeremy JY, Morgan RJ, Mikhailidis DP 1999 Nitric oxide and penile erection: is erectile dysfunction another manifestation of vascular disease? Cardiovasc Res 43:658-665
404. De Angelis L, Marfella MA, Siniscalchi M, Marino L, Nappo F, Giugliano F, De Lucia D, Giugliano D 2001 Erectile and endothelial dysfunction in type II diabetes: a possible link. Diabetologia 44:1155-1160
405. Virag R 2002 Flow-dependent dilatation of the cavernous artery. A potential test of penile NO content. J Mal Vasc 27:214-217